at Zacks.com (Fri, 10:54AM)
Eli Lilly (LLY -1.1%), Amylin (AMLN -24.7%) and Alkermes (ALKS -14.9%) provide top-line results from a head-to-head study, showing investigational diabetes therapy Bydureon didn't meet the pre-specified primary endpoint of non-inferiority to Victoza (NVO +5%). (PR)
How did this change your view of ?
More Bullish More Bearish It Didn't
This impact ()
Thanks for sharing your thoughts.
Submit & View Results
From other sites
at CNBC.com (Fri, 8:06AM)
at Zacks.com (Fri, 7:50AM)
at Zacks.com (Thu, 4:30PM)
at Benzinga.com (Jan 15, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs